Ozempic Gastroparesis Attorney: Statute of Limitations for Ozempic in Virginia

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Exposure Analysis

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy context emphasized broad awareness of wellness, disease management, and the importance of informed patient-provider communication. Within this framework, discussions of pharmaceutical interventions naturally focused on therapeutic benefits and standard risk disclosures, often framed in terms of population-level outcomes rather than individual exposure pathways. As the informational landscape evolves, a more granular focus has emerged on specific drug exposures and their potential downstream consequences. One such area of heightened attention involves glucagon-like peptide-1 receptor agonists, including the medication Ozempic. Originally developed for metabolic regulation, these agents have seen widespread use, prompting closer examination of their long-term safety profiles. In particular, reports of gastroparesis—a condition characterized by delayed gastric emptying—have raised questions about the relationship between sustained drug exposure and gastrointestinal motility disturbances. This shift from general health education to targeted exposure analysis necessitates a careful consideration of legal and regulatory frameworks. For individuals in Virginia who have used Ozempic and subsequently developed gastroparesis, understanding the applicable statute of limitations becomes a critical concern. The transition from broad health literacy to specific occupational or therapeutic exposure contexts requires precise attention to temporal and jurisdictional boundaries that govern potential claims.

Bridging General Awareness to Specific Risk: Ozempic and Gastroparesis

Building on the legacy of general health information, this article now focuses on the specific intersection of Ozempic use and gastroparesis, particularly for Virginia patients. The following sections detail the medical evidence linking Ozempic to gastrointestinal adverse reactions, the adequacy of product warnings, and the legal considerations including the statute of limitations for filing a claim in Virginia. This targeted analysis aims to provide actionable information for individuals who may have been affected.

Medical Evidence: Ozempic and Gastrointestinal Adverse Reactions

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, where a delay in the emptying of a solid meal is documented. The condition can significantly impair quality of life and nutritional status. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes. Its pharmacology includes slowing of gastric emptying, which contributes to its glucose-lowering effects. However, this mechanism also underlies a range of gastrointestinal adverse reactions. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Beyond the common symptoms, less frequent but clinically significant gastrointestinal adverse reactions have been reported. These include dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While the label does not explicitly list gastroparesis as a separate adverse reaction, the constellation of symptoms—particularly nausea, vomiting, dyspepsia, and gastroesophageal reflux—overlaps with the clinical presentation of gastroparesis. The mechanistic pathway linking Ozempic to gastroparesis involves the drug’s known effect on delaying gastric emptying, which can become pathological in susceptible individuals, leading to symptomatic gastroparesis.

Risk Context: Adequacy of Warnings and Legal Considerations for Virginia Patients

The adequacy of warnings regarding Ozempic and gastroparesis is a key risk consideration. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions but does not specifically warn about gastroparesis as a distinct adverse event. The label notes that serious hypersensitivity reactions, such as anaphylaxis and angioedema, have been reported, and that caution is advised in patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific warning about gastroparesis may leave patients and healthcare providers unaware of the potential for this serious complication. This gap in risk communication could be relevant for patients who develop persistent gastrointestinal symptoms after starting Ozempic. For affected patients in Virginia, attorney-related considerations are important. The statute of limitations for personal injury claims in Virginia is generally two years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For claims involving Ozempic and gastroparesis, the timeline between exposure and documented harm is critical. Patients who began taking Ozempic and later developed symptoms consistent with gastroparesis should document the onset of symptoms, the date of diagnosis, and any medical records linking the condition to the medication. The statute of limitations may begin to run from the date of diagnosis or from when the patient became aware of the potential link between Ozempic and their symptoms. Given the complexity of these cases, consulting with an attorney experienced in pharmaceutical litigation is advisable to ensure that claims are filed within the applicable time frame.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Virginia?

In Virginia, the statute of limitations for personal injury claims is generally two years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For Ozempic-related gastroparesis, this may begin from the date of diagnosis or when the patient became aware of the potential link between the medication and their symptoms. It is crucial to consult an attorney promptly to ensure compliance with the filing deadline.

Does Ozempic cause gastroparesis?

Ozempic (semaglutide) is known to slow gastric emptying, which can lead to gastrointestinal symptoms such as nausea, vomiting, and dyspepsia. While the prescribing information does not explicitly list gastroparesis as a separate adverse reaction, the overlapping symptom profile and the drug's mechanism suggest a plausible link. Clinical trials have shown higher rates of gastrointestinal adverse reactions with Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.